4月22日 - ** 制药商百时美施贵宝BMY.N股价盘后下跌6.8%至46.41美元
** BMY称其药物Cobenfy在一项研究精神分裂症附加治疗的后期试验中未能 (link)，与安慰剂相比没有显示出显著的统计学差异。
** 9月，美国食品和药物管理局批准了这种药物，使其成为几十年来第一种新型抗精神病药物。
** BMY 在 2023 年以 140 亿美元收购了卡鲁纳治疗公司（Karuna Therapeutics） (link)，从而获得了药物 Cobenfy（又称 KarXT
** 今年迄今为止，截至上次收盘，BMY 的股价下跌了约 12%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.